 A message from SCD Media LLC |
 NanoViricides, Inc. (NYSE American: NNVC) is at the forefront of a potential medical revolution with its lead drug NV-387, now advancing into Phase II clinical trials. NV-387 is not just a powerful broad-spectrum antiviral—it may also prevent the recurrence of metastatic cancer in patients in remission! Research shows that viral infections, including COVID-19, Influenza, RSV, and measles, can awaken dormant cancer cells, driving metastasis. NV-387 works on two fronts: it attacks the virus while reducing harmful inflammation, particularly IL-6 cytokines, which studies link to cancer cell reactivation. In preclinical studies, NV-387 protected lungs from lethal viral infections while dramatically lowering inflammatory markers, outperforming existing antivirals like Tamiflu and Xofluza. This means NV-387 has unique first-in-class potential, combining lifesaving antiviral efficacy with groundbreaking cancer-prevention effects. The implications for patients and the market are massive. With viral infections surging globally and no therapy currently addressing both viral threats and the risk of metastatic cancer recurrence, NNVC’s NV-387 is positioned to meet a critical unmet medical need. NanoViricides’ exclusive nanoviricide™ platform technology ensures viruses cannot escape, even as new variants emerge, giving the drug a rare competitive edge. This is a company pioneering dual-benefit therapies that could transform antiviral treatment and cancer care simultaneously. With Phase II trials on the horizon, the clinical, commercial, and societal potential of NV-387 is extraordinary.
|
| This is a paid advertisement provided to customers of Schaeffer's Investment Research. Although we have sent you this email, Schaeffer's does not necessarily endorse this product nor is it responsible for the content of this advertisement. Schaeffer's makes no guarantee or warranty about what is advertised above. |
0 Response to "Biotech Breakthrough: NanoViricides Advances Dual-Action Drug Into Trials"
Post a Comment